Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.60

-1.1%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$278.10M
EPS-1.4000
P/E Ratio-1.97
Earnings Date08/12/2026

catx

Depreciation and Amortization

Last Annual Value

3.25M

3-Year CAGR

111%

5-Year CAGR

85%

10-Year CAGR

21%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of Depreciation and Amortization

CATX · AMEX
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.25M
50.9%67.3%47.2% 
626.00K
-2.9%6.2%N/A
1.17M
24.1%14.0%4.7%
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
5.14M
4.0%29.3%47.5%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
2.11M
1.3%362.1%N/A
3.46M
20.0%26.7%17.8%
HSDT logo
Solana Company
NASDAQ:HSDT
680.00K
61.3%12.7%N/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.6, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.6